Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: The present disclosure is directed to a chewable matrix that can be used as a tool for collection of saliva samples. Also disclosed herein are methods for extracting saliva, and in particular microorganisms or nucleic acid, from the chewable matrix, methods for detecting an illness or infection in subjects using the chewable matrix, and kits for performing these methods.

Abstract: A chewing gum base comprises rubber derived from Russian Dandelion (TKS). Methods of extracting and purifying the rubber are provided. Gum base compositions and methods of compensating for variable ratios of elastomer:resin in the rubber are disclosed.

Abstract: The present disclosure is directed to medium chain length polyhydroxyalkanoate (mcl-PHA) copolymers, and to chewing gum bases and chewing gums comprising the mcl-PHA copolymers. In some instances, the mcl-PHA copolymers may partially or completely replace conventional petroleum-based gum base polymers, including elastomers, in the chewing gum and gum base. The chewing gums and gum bases of the present disclosure may be free or substantially free of petroleum-based ingredients. Chewing gums comprising the mcl-PHA copolymers of the present disclosure may also have enhanced degradability as compared to conventional chewing gums.

Abstract: The present disclosure is directed to chewing gum bases, where mineral filler in the gum base formulation has been replaced with a polyol. The chewing gum bases of the present disclosure are thus essentially free of mineral filler, and contain a polyol, such as mannitol. Also disclosed are processes for producing the chewing gum bases. The processes of the present disclosure utilize polyol as a replacement for mineral fillers during various production stages. Confectionery products, such as chewing gums, that comprise the chewing gum bases are also disclosed.

Abstract: A method is provided for making a molten, deposited confectionery product, such as a chewing gum product. In an embodiment of the method for making a chewing gum product, one or more sugar alcohols are blended and melted before adding gum base and other ingredients. The process allows depositing at cooler temperatures than previously believed possible, which simplifies safe processing and protects product quality. In cases where the product is deposited in molds which are part of the packaging, the lower depositing temperatures allow greater flexibility in packaging materials and processes than when the sugar alcohols and other ingredients such as gum base are melted together. A product of the method also is provided.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: A multi-piece dispenser for confectionary products including a housing defining an inner chamber for storing a multi-piece package of confectionary product including a slot for receiving an end portion of the multi-piece package for dispensing the confectionary product and a retention member for retaining the end portion of the package within the slot for further dispensing.

Abstract: Dried fruit powders are used as a replacement for current bulking agents used in chewing gum, such as polyols or sucrose, thereby providing healthier chewing gum options to consumers with real fruit taste.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: A chewing gum base comprises rubber derived from Russian Dandelion (TKS). Methods of extracting and purifying the rubber are provided. Gum base compositions and methods of compensating for variable ratios of elastomer: resin in the rubber are disclosed.

Abstract: Chewing gums and chewing gum bases having at least one natural elastomer or natural elastomer system and at least one edible additive are disclosed.

Abstract: A gum base which, when formulated into a chewing gum, provides a gum base composition made with synthetic elastomers and elastomers plasticizers obtained from “green” or renewable and sustainable resources.

Abstract: The present invention describes a process wherein a liquid chewing gum is deposited onto a surface to form deposits of a chewing gum product. The individual deposits of chewing gum can then undergo further packaging and wrapping to form a commercially acceptable chewing gum product.

Abstract: A multi-piece dispenser for confectionary products including a housing defining an inner chamber for storing a multi-piece package of confectionary product including a slot for receiving an end portion of the multi-piece package for dispensing the confectionary product and a retention member for retaining the end portion of the package within the slot for further dispensing.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.